# US 10,118,943 B2 · Compounds and methods for inhibiting cell death

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,118,943 B2
- Document ID: US10118943B2
- Status: Granted
- Kind: B2
- Application number: 14/401,504
- Filed: 2013-03-12
- Published: 2015-05-21
- Granted: 2018-11-06
- Earliest claimed: 2012-05-16
- Assignees: Ramot at Tel-Aviv University Ltd.
- Applicants: Ramot at Tel-Aviv University Ltd.
- Inventors: Illana Gozes; Saar Oz; Jacqueline Woang Cheing Tiong
- Web page: https://patentgrep.com/patent/US10118943B2

## CPC

- C07K 5/10: Tetrapeptides
- C07K 5/1013: {the side chain containing O or S as heteroatoms, e.g. Cys, Ser}
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- G01N 33/56966: {Animal cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides novel compounds and methods for promoting cell survival and/or plasticity, especially in neuronal cells, by targeting the microtubule End Binding (EB) proteins and other associated proteins (e.g., drebrin). Methods for identifying potential modulators of cell death/plasticity are also described.

## Claims

### Claim 1

An isolated peptide consisting of the amino acid sequence of SKIP (SEQ ID NO: 6), which is acetylated at the N-terminus and amidated at the C-terminus in an effective amount to inhibit cell death or increase cell plasticity.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the amino acid sequence of SKIP (SEQ ID NO:6) comprises at least one D-amino acid.

### Claim 3 (depends on 2)

The peptide of claim 2, wherein the amino acid sequence of SKIP (SEQ ID NO:6) is all D-amino acid SKIP.

### Claim 4 (depends on 1)

The peptide of claim 1, wherein the cell is a neuronal cell.

### Claim 5 (depends on 1)

A composition comprising the peptide of claim 1 and a pharmaceutically acceptable excipient.

### Claim 6 (depends on 5)

The composition of claim 5, which is formulated for oral or nasal administration.

### Claim 7 (depends on 1)

A method for promoting cell survival or plasticity, comprising contacting a cell with the peptide of claim 1 in an amount that is effective to increase the expression of an EB protein.

### Claim 8 (depends on 7)

The method of claim 7, wherein the EB protein is an EB1 protein, or an EB2 protein, or an EB3 protein.

### Claim 9 (depends on 7)

The method of claim 7, wherein the cell is a neuronal cell.

### Claim 10 (depends on 7)

The method of claim 7, wherein the cell is present in a patient's body.

### Claim 11 (depends on 7)

The method of claim 7, wherein the amino acid sequence of SKIP (SEQ ID NO:6) is all D-amino acid SKIP.

### Claim 12 (depends on 7)

The method of claim 7, comprising a step of administering the peptide to a patient diagnosed of cognitive impairment.